Market Overview

UPDATE: Piper Jaffray Upgrades Medidata Solutions to Overweight on Revenue Growth

Share:
Related MDSO
Medidata (MDSO), inVentiv Enter Into Multi-Year Partnership
Medidata Solutions (MDSO) Set to Join the S&P 400 Index
Nasdaq Reverses Lower: Top Internet Stock Dives Below Buy Zone (Investor's Business Daily)

Piper Jaffray raised its rating on Medidata Solutions (NASDAQ: MDSO) from Neutral to Overweight and increased its target price from $31 to $54.

Piper Jaffray commented, "We've always viewed the cloud as a better model for health care, but initially we failed to see the implications for the clinical trials market. We get it now. And because Medidata has the only cloud-based EDC application on the market, we believe the current sales momentum is sustainable. Growing at this rate is no easy task, it will take added investments to support an accelerating top line growth rate. We're fine with that. This is a SaaS model that we believe will grow 20% top line next year with a 99% retention rate, and huge opportunities to cross-sell and grow market share."

Medidata Solutions closed at $42.02 on Wednesday.

Latest Ratings for MDSO

DateFirmActionFromTo
Jun 2017Bank of AmericaInitiates Coverage OnBuy
May 2017JefferiesUpgradesUnderperformHold
Feb 2017SunTrust Robinson HumphreyUpgradesHoldBuy

View More Analyst Ratings for MDSO
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (MDSO)

View Comments and Join the Discussion!